The evolution of prostate cancer therapy: targeting the androgen receptor

The evolution of prostate cancer therapy: targeting the androgen receptor

Item
http://www.wikidata.org/entity/Q38266909
Targeting Transcription Factors in CancerPROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.KLF4 functions as an activator of the androgen receptor through reciprocal feedback.Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistanceRNA-based ovarian cancer research from 'a gene to systems biomedicine' perspective.Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.Molecular signatures of ovarian diseases: Insights from network medicine perspective.Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report.Identification of potential therapeutic targets in prostate cancer through a cross-species approach.Isobavachalcone Induces ROS-Mediated Apoptosis Targeting Thioredoxin Reductase 1 in Human Prostate Cancer PC-3 Cells
P2860

The evolution of prostate cancer therapy: targeting the androgen receptor

Item
http://www.wikidata.org/entity/Q38266909
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The evolution of prostate cancer therapy: targeting the androgen receptor
@en
type
label
The evolution of prostate cancer therapy: targeting the androgen receptor
@en
prefLabel
The evolution of prostate cancer therapy: targeting the androgen receptor
@en
P1433
P1476
P2860
P304
P31
P356
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
The evolution of prostate cancer therapy: targeting the androgen receptor
@en
P2860
P304
P31
P356
P478
P50
P577
P5875
P698
P932